AdvanCell strengthens cancer drug pipeline with $112m Series C funding

AdvanCell, a clinical-stage radiopharmaceutical company specializing in targeted alpha therapy, has successfully completed an oversubscribed $112 million Series C funding round. The investment, co-led by ... Read More